Rizatriptan Benzoate

Warning

Rizatriptan Benzoate may cause serious cardiovascular side effects, including myocardial infarction, stroke, and vasospasm. It is contraindicated in patients with certain cardiovascular conditions.

Contraindications

• Ischemic heart disease or coronary artery vasospasm
• History of stroke or transient ischemic attack
• Peripheral vascular disease
• Ischemic bowel disease
• Uncontrolled hypertension
• Recent use of another 5-HT1 agonist or ergotamine-containing medication

Adverse Reactions

• Asthenia/fatigue
• Somnolence
• Pain/pressure sensation
• Dizziness
• Nausea
• Dry mouth

General Guidance

The dose of Rizatriptan Benzoate should be adjusted in propranolol-treated patients, and the maximum daily dose should not exceed 30 mg in any 24-hour period.

Pregnancy

• Available human data are not sufficient to draw conclusions about drug-associated risk for major birth defects and miscarriage
• Developmental toxicity was observed in animal studies

Nursing Mothers

• There are no data on the presence of Rizatriptan Benzoate in human milk
• Rizatriptan was excreted in rat milk

Pediatric Use

• Safety and effectiveness in pediatric patients under 6 years of age have not been established
• The efficacy and safety of Rizatriptan Benzoate in the acute treatment of migraine in patients aged 6 to 17 years was established in an adequate and well-controlled study

Geriatric Use

• Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects
• Dose selection for an elderly patient should be cautious, starting at the low end of the dosing range